Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
Cancer Pathogenesis and Therapy2025cited by 2position: middledoi
Insights into the roles of lncRNAs in skeletal and dental diseases
Cell & Bioscience2018cited by 16position: middledoi